The annual recurrence risk model for tailored surveillance
strategy in patients with cervical cancer

J 2021

The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer

CIBULA, David; Luaks DOSTALEK; Jiří JARKOVSKÝ; C. H. MOM; A. LOPEZ et al.

Základní údaje

Originální název

The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer

Autoři

Vydání

European Journal of Cancer, Oxford, Elsevier Science Inc. 2021, 0959-8049

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 10.002

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/21:00122899

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Cervical cancer; Surveillance; Prognostic model; Annual recurrence risk

Štítky

14110411, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 22. 11. 2021 13:17, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: Current guidelines for surveillance strategy in cervical cancer are rigid, recommending the same strategy for all survivors. The aim of this study was to develop a robust model allowing for individualised surveillance based on a patient's risk profile. Methods: Data of 4343 early-stage patients with cervical cancer treated between 2007 and 2016 were obtained from the international SCCAN (Surveillance in Cervical Cancer) consortium. The Cox proportional hazards model predicting disease-free survival (DFS) was developed and internally validated. The risk score, derived from regression coefficients of the model, stratified the cohort into significantly distinctive risk groups. On its basis, the annual recurrence risk model (ARRM) was calculated. Results: Five variables were included in the prognostic model: maximal pathologic tumour diameter; tumour histotype; grade; number of positive pelvic lymph nodes; and lymphovascular space invasion. Five risk groups significantly differing in prognosis were identified with a five-year DFS of 97.5%, 94.7%, 85.2% and 63.3% in increasing risk groups, whereas a two-year DFS in the highest risk group equalled 15.4%. Based on the ARRM, the annual recurrence risk in the lowest risk group was below 1% since the beginning of follow-up and declined below 1% at years three, four and >5 in the medium-risk groups. In the whole cohort, 26% of recurrences appeared at the first year of the follow-up, 48% by year two and 78% by year five. Conclusion: The ARRM represents a potent tool for tailoring the surveillance strategy in early-stage patients with cervical cancer based on the patient's risk status and respective annual recurrence risk. It can easily be used in routine clinical settings internationally. (c) 2021 Elsevier Ltd. All rights reserved.

Citovat

CIBULA, David; Luaks DOSTALEK; Jiří JARKOVSKÝ; C. H. MOM; A. LOPEZ; H. FALCONER; A. FAGOTTI; A. AYHAN; S. H. KIM; D. I. ORTIZ; J. KLAT; A. OBERMAIR; F. LANDONI; J. RODRIGUEZ; R. MANCHANDA; J. KOSTUN; R. DOS REIS; M. M. MEYDANLI; D. ODETTO; R. LAKY; I. ZAPARDIEL; Vít WEINBERGER; Klára BENEŠOVÁ; Martina BORCINOVA; D. PARI; S. SALEHI; N. BIZZARRI; H. AKILLI; N. R. ABU-RUSTUM; R. A. SALCEDO-HERNANDEZ; Veronika JAVURKOVA; Jiri SLAMA a L. R. C. W. VAN LONKHUIJZEN. The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer. European Journal of Cancer. Oxford: Elsevier Science Inc., 2021, roč. 158, November 2021, s. 111-122. ISSN 0959-8049. Dostupné z: https://doi.org/10.1016/j.ejca.2021.09.008.

@article{1804601,
   author = {Cibula, David and Dostalek, Luaks and Jarkovský, Jiří and Mom, C. H. and Lopez, A. and Falconer, H. and Fagotti, A. and Ayhan, A. and Kim, S. H. and Ortiz, D. I. and Klat, J. and Obermair, A. and Landoni, F. and Rodriguez, J. and Manchanda, R. and Kostun, J. and dos Reis, R. and Meydanli, M. M. and Odetto, D. and Laky, R. and Zapardiel, I. and Weinberger, Vít and Benešová, Klára and Borcinova, Martina and Pari, D. and Salehi, S. and Bizzarri, N. and Akilli, H. and AbuandRustum, N. R. and SalcedoandHernandez, R. A. and Javurkova, Veronika and Slama, Jiri and van Lonkhuijzen, L. R. C. W.},
   article_location = {Oxford},
   article_number = {November 2021},
   doi = {https://doi.org/10.1016/j.ejca.2021.09.008},
   keywords = {Cervical cancer; Surveillance; Prognostic model; Annual recurrence risk},
   language = {eng},
   issn = {0959-8049},
   journal = {European Journal of Cancer},
   title = {The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer},
   url = {https://www.sciencedirect.com/science/article/pii/S0959804921006031?via%3Dihub},
   volume = {158},
   year = {2021}
}

TY  - JOUR
ID  - 1804601
AU  - Cibula, David - Dostalek, Luaks - Jarkovský, Jiří - Mom, C. H. - Lopez, A. - Falconer, H. - Fagotti, A. - Ayhan, A. - Kim, S. H. - Ortiz, D. I. - Klat, J. - Obermair, A. - Landoni, F. - Rodriguez, J. - Manchanda, R. - Kostun, J. - dos Reis, R. - Meydanli, M. M. - Odetto, D. - Laky, R. - Zapardiel, I. - Weinberger, Vít - Benešová, Klára - Borcinova, Martina - Pari, D. - Salehi, S. - Bizzarri, N. - Akilli, H. - Abu-Rustum, N. R. - Salcedo-Hernandez, R. A. - Javurkova, Veronika - Slama, Jiri - van Lonkhuijzen, L. R. C. W.
PY  - 2021
TI  - The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer
JF  - European Journal of Cancer
VL  - 158
IS  - November 2021
SP  - 111-122
EP  - 111-122
PB  - Elsevier Science Inc.
SN  - 09598049
KW  - Cervical cancer
KW  - Surveillance
KW  - Prognostic model
KW  - Annual recurrence risk
UR  - https://www.sciencedirect.com/science/article/pii/S0959804921006031?via%3Dihub
N2  - Purpose: Current guidelines for surveillance strategy in cervical cancer are rigid, recommending the same strategy for all survivors. The aim of this study was to develop a robust model allowing for individualised surveillance based on a patient's risk profile. Methods: Data of 4343 early-stage patients with cervical cancer treated between 2007 and 2016 were obtained from the international SCCAN (Surveillance in Cervical Cancer) consortium. The Cox proportional hazards model predicting disease-free survival (DFS) was developed and internally validated. The risk score, derived from regression coefficients of the model, stratified the cohort into significantly distinctive risk groups. On its basis, the annual recurrence risk model (ARRM) was calculated. Results: Five variables were included in the prognostic model: maximal pathologic tumour diameter; tumour histotype; grade; number of positive pelvic lymph nodes; and lymphovascular space invasion. Five risk groups significantly differing in prognosis were identified with a five-year DFS of 97.5%, 94.7%, 85.2% and 63.3% in increasing risk groups, whereas a two-year DFS in the highest risk group equalled 15.4%. Based on the ARRM, the annual recurrence risk in the lowest risk group was below 1% since the beginning of follow-up and declined below 1% at years three, four and >5 in the medium-risk groups. In the whole cohort, 26% of recurrences appeared at the first year of the follow-up, 48% by year two and 78% by year five. Conclusion: The ARRM represents a potent tool for tailoring the surveillance strategy in early-stage patients with cervical cancer based on the patient's risk status and respective annual recurrence risk. It can easily be used in routine clinical settings internationally. (c) 2021 Elsevier Ltd. All rights reserved.
ER  -

CIBULA, David; Luaks DOSTALEK; Jiří JARKOVSKÝ; C. H. MOM; A. LOPEZ; H. FALCONER; A. FAGOTTI; A. AYHAN; S. H. KIM; D. I. ORTIZ; J. KLAT; A. OBERMAIR; F. LANDONI; J. RODRIGUEZ; R. MANCHANDA; J. KOSTUN; R. DOS REIS; M. M. MEYDANLI; D. ODETTO; R. LAKY; I. ZAPARDIEL; Vít WEINBERGER; Klára BENEŠOVÁ; Martina BORCINOVA; D. PARI; S. SALEHI; N. BIZZARRI; H. AKILLI; N. R. ABU-RUSTUM; R. A. SALCEDO-HERNANDEZ; Veronika JAVURKOVA; Jiri SLAMA a L. R. C. W. VAN LONKHUIJZEN. The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer. \textit{European Journal of Cancer}. Oxford: Elsevier Science Inc., 2021, roč.~158, November 2021, s.~111-122. ISSN~0959-8049. Dostupné z: https://doi.org/10.1016/j.ejca.2021.09.008.

Přehled o publikaci